Scinai Immunotherapeutics Ltd.
SCNI
$0.51
-$0.03-5.07%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.43% | 10.98% | 4.29% | -- | -42.02% |
| Total Depreciation and Amortization | -28.16% | -29.03% | 494.05% | -- | 2.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.06% | -59.16% | 106.17% | -- | 260.94% |
| Change in Net Operating Assets | -140.95% | 191.09% | -87.94% | -- | -545.14% |
| Cash from Operations | -60.59% | 26.76% | 12.16% | -- | -176.83% |
| Capital Expenditure | -- | 0.00% | 100.00% | -- | 98.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00% | 100.00% | -- | 98.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -44.84% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.73% | 6,487.50% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -1,125.00% | 117.36% | 114.29% | -- | 37.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.28% | 72.49% | 162.86% | -- | -65.69% |